Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 12-Week, Exploratory, Open-Label, Nonrandomized, Dose-Escalation Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe, Recalcitrant, Plaque Type Psoriasis

NCT00236119 is registered in ClinicalTrials.gov with Cephalon as lead sponsor.

NCT NCT00236119
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00236119 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 12-Week, Exploratory, Open-Label, Nonrandomized, Dose-Escalation Study of the Efficacy, Safety and Tolerability of Oral CEP-701 in Patients With Severe, Recalcitrant, Plaque Type Psoriasis
Lead sponsor
Cephalon
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2005
Completion date
October 31, 2007
Enrollment
46 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

psoriasis